- Home
- QNST vs IVA Comparison
QNST vs IVA Comparison
Compare QNST & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- IVA
- Stock Information
- Founded
- QNST 1999
- IVA 2011
- Country
- QNST United States
- IVA France
- Employees
- QNST N/A
- IVA N/A
- Industry
- QNST Business Services
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- IVA Health Care
- Exchange
- QNST Nasdaq
- IVA Nasdaq
- Market Cap
- QNST 923.2M
- IVA 769.0M
- IPO Year
- QNST 2010
- IVA 2020
- Fundamental
- Price
- QNST $14.50
- IVA $5.28
- Analyst Decision
- QNST Buy
- IVA Strong Buy
- Analyst Count
- QNST 6
- IVA 7
- Target Price
- QNST $27.33
- IVA $16.57
- AVG Volume (30 Days)
- QNST 508.9K
- IVA 124.5K
- Earning Date
- QNST 11-03-2025
- IVA 09-29-2025
- Dividend Yield
- QNST N/A
- IVA N/A
- EPS Growth
- QNST N/A
- IVA N/A
- EPS
- QNST 0.08
- IVA N/A
- Revenue
- QNST $1,093,711,000.00
- IVA $19,929,536.00
- Revenue This Year
- QNST $10.72
- IVA N/A
- Revenue Next Year
- QNST $9.66
- IVA N/A
- P/E Ratio
- QNST $177.50
- IVA N/A
- Revenue Growth
- QNST 78.27
- IVA N/A
- 52 Week Low
- QNST $13.56
- IVA $2.11
- 52 Week High
- QNST $26.27
- IVA $6.55
- Technical
- Relative Strength Index (RSI)
- QNST 42.16
- IVA 49.41
- Support Level
- QNST $13.91
- IVA $4.70
- Resistance Level
- QNST $14.69
- IVA $5.47
- Average True Range (ATR)
- QNST 0.58
- IVA 0.43
- MACD
- QNST -0.09
- IVA -0.10
- Stochastic Oscillator
- QNST 38.63
- IVA 40.43
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.